Clinical Trials Logo

Milk Allergy clinical trials

View clinical trials related to Milk Allergy.

Filter by:

NCT ID: NCT05309772 Recruiting - Food Allergy Clinical Trials

The Clinical Impact of the Basophil Activation Test to Diagnose Food Allergy

Start date: January 13, 2023
Phase: N/A
Study type: Interventional

The BAT Impact study is a prospective multicentre study in the UK using a biomarker-led study design to compare the incidence of adverse events (defined as allergic reactions during oral food challenges) in a randomized-controlled trial. Patients will either follow the standard-of-care (i.e. an oral food challenge in case of equivocal SPT/sIgE) or follow a basophil activation test (BAT)/mast cell activation test (MAT)-based strategy, i.e. patients with a positive BAT or MAT are dispensed of an oral food challenge (OFC) and patients with a negative BAT/MAT undergo an OFC.

NCT ID: NCT04318483 Completed - Milk Allergy Clinical Trials

Characteristic and Evolution of an Atypical IgE-mediated Cow Milk Allergy Form With Hands and Feet Angio-oedema

IgE-CMA
Start date: May 4, 2020
Phase:
Study type: Observational

Cow milk allergy is one of the most frequent food allergy among children. Cow milk protein's avoidance is needed until spontaneous recovery during the two first years of life. A atypical clinical form with angio-oedema of hands and feet which is associated with high rate of lactoserum's IgE might be a hope of an earlier recovery.

NCT ID: NCT03819556 Recruiting - Milk Allergy Clinical Trials

Swedish Study of Immunotherapy for Milk Allergy in Children

SWITCH
Start date: April 20, 2018
Phase: N/A
Study type: Interventional

This trial is a two-armed open randomized controlled trial in children aged 5-15 years with challenge proven Immunoglobulin E (IgE)-associated milk allergy.The purpose is to determine if oral immunotherapy with milk can induce tolerance to milk. The active intervention is intake of increasing amounts of fresh milk for six months followed by three years of maintenance treatment with milk. The control group continues their elimination (milk free) diet. The trial will recruit patients at ten pediatric departments in Sweden, coordinated by Umeå University. The primary outcome is milk tolerance (defined as a negative double-blind placebo-controlled milk challenge) at trial completion 3.5 years after start of treatment. Secondary outcomes include allergic symptoms during treatment documented as certain allergic manifestations, changes in immunological and microbial biomarkers, quality of life and nutritional status.

NCT ID: NCT03309488 Recruiting - Food Allergy Clinical Trials

Basophil Activation Test to Diagnose Food Allergy

BAT2
Start date: January 30, 2018
Phase:
Study type: Observational

The BAT II Study is a cross-sectional diagnostic study in which children with suspected IgE-mediated allergy to foods (namely cow's milk, egg, sesame and cashew), as defined by a history of an immediate-type allergic reaction to a food or no history of food consumption or the presence of food-specific IgE as documented by skin prick test or serum specific IgE, will undergo a diagnostic work-up to confirm or refute the diagnosis of IgE-mediated food allergy. Participants will be prospectively recruited from specialised Paediatric Allergy clinics in London and will undergo skin prick testing (SPT), specific IgE testing to allergen extracts and allergen components, basophil activation test (BAT) and oral food challenge. The diagnostic accuracy of the BAT and of other allergy tests will be assessed against the clinical gold-standard.

NCT ID: NCT02719405 Terminated - Milk Allergy Clinical Trials

Impact of Infant Formula on Resolution of Cow's Milk Allergy

Start date: February 2016
Phase: Phase 2
Study type: Interventional

Primary Endpoint -The percentage of subjects who develop tolerance to cow's milk protein by 12 months post randomization to study formula. Secondary Endpoints - Tolerance - The transcriptional profile of milk-specific T cells by clinical outcome. - Growth and Weight Velocity - Stool Consistency and Frequency - The estimated frequency of milk-specific T cells by clinical outcome. - The TCR diversity of milk-specific T cells by clinical outcome. - The milk allergen component-specific IgE, IgG4 and IgA by clinical outcome. - Safety - The rate of reported adverse events by treatment group.

NCT ID: NCT02579876 Completed - Clinical trials for Eosinophilic Esophagitis

Milk Patch for Eosinophilic Esophagitis

SMILEE
Start date: October 2015
Phase: Phase 2
Study type: Interventional

This is a single-site, double-blind, placebo-controlled, randomized trial to study efficacy and safety of the Viaskin® Milk Patch for children with milk induced Eosinophilic Esophagitis (EoE). 20 subjects will be randomized 3:1 to Viaskin® Milk or placebo patch.

NCT ID: NCT02317952 Completed - Milk Allergy Clinical Trials

Formula for Children With Cow's Milk Allergy

Start date: May 2014
Phase: N/A
Study type: Interventional

The purpose of this study is to determine if a new extensively hydrolyzed formula can be consumed by children with Cow's Milk Allergy.

NCT ID: NCT01950533 Completed - Peanut Allergy Clinical Trials

The Utility of Food-Specific IgE Measured With the IMMULITE 2000 Assay to Predict Symptomatic Food Allergy

IMMULITE 2000
Start date: September 2013
Phase:
Study type: Observational

Food allergy is on the rise within the pediatric population. Having food allergy can cause medical, nutritional and psychological issues in those who suffer with it. Although making the appropriate diagnosis of food allergy is very important, properly diagnosing food allergy has been a challenge. Skin prick testing and food-specific IgE testing of the blood can give positive results that are false. Currently, Oral Food Challenges are the best way to diagnose a food allergy. Unfortunately, Oral Food Challenges are time consuming and may not be readily available to suspected food allergy sufferers. This study is designed to examine the effectiveness of an allergy-detecting blood test called IMMULITE 2000 manufactured by the study sponsor, Siemens.

NCT ID: NCT01361347 Completed - Anaphylaxis Clinical Trials

Safety of Oral Immunotherapy for Cow's Milk Allergy in School-aged Children

Start date: February 2008
Phase: Phase 4
Study type: Interventional

The purpose of this study is to study the number of Participants with Adverse Events as a Measure of Safety and Tolerability.

NCT ID: NCT01157117 Completed - Milk Allergy Clinical Trials

OIT and Xolair® (Omalizumab) in Cow's Milk Allergy

Start date: August 2010
Phase: Phase 2
Study type: Interventional

Food allergy affects up to 4% of the U.S. population and is most common in young children. Milk allergy is the most common cause of food allergy in infants and young children, and usually develops in the first year of life. There is no treatment for food allergy and the current standard of care for milk-allergic individuals is the avoidance of milk-containing products. Research is underway to identify potential therapeutic strategies to reduce or eliminate the adverse effects experienced by milk-allergic individuals when they consume milk-containing products. Several studies have suggested that milk-allergic children who receive milk protein oral immunotherapy (OIT) may become desensitized to milk, resulting in short term protection against accidental ingestion of milk products. However, these children did not develop "tolerance," which is long term protection even after milk immunotherapy is stopped. A potential strategy to induce tolerance to milk uses milk in combination with Xolair® (omalizumab). Xolair consists of anti-IgE molecules that attach to IgE, the major antibody involved in allergic reactions. The goal of this clinical trial is to see whether Xolair® in combination with milk protein OIT is safer and more effective than OIT alone in inducing tolerance to milk and milk products. Participants will be administered a double blind, placebo controlled milk challenge at various time points in the study. If desensitization is achieved participants will be tested for tolerance at a certain time point after stopping treatment.